A
A Wajgt
Researcher at University of Silesia in Katowice
Publications - 18
Citations - 4180
A Wajgt is an academic researcher from University of Silesia in Katowice. The author has contributed to research in topics: Natalizumab & Multiple sclerosis. The author has an hindex of 9, co-authored 18 publications receiving 3910 citations.
Papers
More filters
Journal ArticleDOI
A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis
Chris H. Polman,Eva Havrdova,Michael Hutchinson,Ludwig Kappos,David Miller,J. Theodore Phillips,Fred D. Lublin,Gavin Giovannoni,A Wajgt,Martin Toal,F Lynn,Michael Panzara,Alfred Sandrock +12 more
TL;DR: Natalizumab reduced the risk of the sustained progression of disability and the rate of clinical relapse in patients with relapsing multiple sclerosis and hold promise as an effective treatment for relapsed multiple sclerosis.
Journal ArticleDOI
MRI outcomes in a placebo-controlled trial of natalizumab in relapsing MS
DH Miller,D Soon,Ktm Fernando,D. G. MacManus,Gareth J. Barker,Tarek A. Yousry,Elizabeth M. C. Fisher,Paul O'Connor,JT Phillips,Chris H. Polman,Ludwig Kappos,Michael Hutchinson,Eva Havrdova,Fred D. Lublin,Gavin Giovannoni,A Wajgt,RA Rudick,F Lynn,Michael Panzara,Alfred Sandrock +19 more
TL;DR: Natalizumab has a sustained effect in preventing the formation of new lesions in patients with relapsing multiple sclerosis.
Journal ArticleDOI
The incidence and significance of anti-natalizumab antibodies: Results from AFFIRM and SENTINEL
Peter A. Calabresi,Gavin Giovannoni,Christian Confavreux,SL Galetta,Eva Havrdova,Michael Hutchinson,Ludwig Kappos,David Miller,Paul O'Connor,JT Phillips,Chris H. Polman,Ernst Wilhelm Radue,RA Rudick,WH Stuart,Fred D. Lublin,A Wajgt,Bianca Weinstock-Guttman,Daniel Wynn,F Lynn,Michael Panzara +19 more
TL;DR: The incidence of persistent antibody positivity associated with natalizumab is 6%.
Journal ArticleDOI
The efficacy of natalizumab in patients with relapsing multiple sclerosis: subgroup analyses of AFFIRM and SENTINEL
Michael Hutchinson,Ludwig Kappos,Peter A. Calabresi,Christian Confavreux,Gavin Giovannoni,SL Galetta,Eva Havrdova,Fred D. Lublin,DH Miller,Paul O'Connor,JT Phillips,Chris H. Polman,Ernst Wilhelm Radue,Richard A. Rudick,WH Stuart,A Wajgt,Bianca Weinstock-Guttman,Daniel Wynn,F Lynn,Michael Panzara +19 more
TL;DR: The AFFIRM and SENTINEL studies showed that natalizumab was effective both as monotherapy and in combination with interferon beta (IFNβ)-1a in patients with relapsing multiple sclerosis (MS) as discussed by the authors.
Journal ArticleDOI
Health-related quality of life in multiple sclerosis: effects of natalizumab
Richard A. Rudick,Deborah M. Miller,Steve Hass,Michael Hutchinson,Peter A. Calabresi,Christian Confavreux,Steven L. Galetta,Gavin Giovannoni,Eva Havrdova,Ludwig Kappos,Fred D. Lublin,David Miller,Paul O'Connor,J. Theodore Phillips,Chris H. Polman,Ernst-Wilhelm Radue,WH Stuart,A Wajgt,Bianca Weinstock-Guttman,Daniel Wynn,F Lynn,Mph Michael A. Panzara Md +21 more
TL;DR: To report the relationship between disease activity and health‐related quality of life (HRQoL) in relapsing multiple sclerosis, and the impact of natalizumab.